Coeptis Therapeutics Holdings, INC 10-Q quarterly reports

Z Squared Inc. reported substantial losses from its crypto mining operations in Q2 2026, while simultaneously advancing plans for AI infrastructure development, funded by recent equity issuances.

Coeptis Therapeutics reported a significant increase in cash and equity driven by capital raises, alongside a strategic shift towards biotechnology and AI-powered marketing, despite widening net losses.

Coeptis Therapeutics reports increased cash and new revenue from its technology segment, alongside a planned biotech spin-out and ongoing significant losses.

Coeptis Therapeutics Holdings, Inc. files its Form 10-Q for the quarter ended March 31, 2025, detailing its financial condition and operational progress in its biotechnology and technology divisions.

Coeptis Therapeutics Holdings reported its third quarter 2024 results, highlighting ongoing product development and strategic partnerships while navigating financial challenges.

Coeptis Therapeutics Holdings reported a net loss of $6.04 million for the six months ended June 30, 2024, while continuing to focus on product development and strategic partnerships.

Coeptis Therapeutics Holdings has filed an amended 10-Q report to reclassify notes receivable as subscription receivables after an accounting evaluation.

Coeptis Therapeutics Holdings, Inc. has filed an amended 10-Q report to reclassify subscription receivables, correcting an accounting error related to note agreements.

Coeptis Therapeutics Holdings reported a net loss of $3.0 million for the first quarter of 2024, while continuing to advance its cell therapy technologies.

Coeptis Therapeutics Holdings, Inc. has filed an amended 10-Q to restate its financial statements for the third quarter of 2023 due to errors in accounting for a convertible note and a research agreement.

Coeptis Therapeutics Holdings, Inc. has filed an amended 10-Q to restate its financials for the second quarter of 2023 due to errors in accounting for a convertible note and a research agreement.

Coeptis Therapeutics Holdings, Inc. has filed an amended quarterly report to restate its financials for the first quarter of 2023 due to errors in accounting for a convertible note and a research agreement.